{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:17:02Z","timestamp":1792109822495,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030840","name":"Iovance Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) is an FDA-approved treatment for metastatic melanoma and continues to be studied in other cancers. As a common site of metastatic disease, the liver is potentially a useful site for TIL procurement, but only if the procedures can be performed with an acceptably low risk of complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was performed on 158 patients who underwent liver resection for TIL procurement between 2000 and 2024. Patients had metastatic melanoma or epithelial cancers. The primary outcomes were 30\u00a0days and 90\u00a0days morbidity and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Liver resection for TIL was performed in 81 patients with melanoma and 77 patients with epithelial cancers. The overall 30\u00a0days and 90\u00a0days mortality were 1% and 10%, respectively, and no deaths were attributed to surgery. Complication rates (Clavien-Dindo \u2265 III) were 5% and 7%, respectively. Viable tumor was confirmed in 100% of resected lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Liver resection for TIL procurement is feasible and safe in carefully selected patients. Candidate patients should be discussed in a multidisciplinary setting with both medical and surgical expertise reaching a consensus on the optimal site selection to minimize risk and maximize therapeutic success.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19242-8","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:44:00Z","timestamp":1771613040000},"page":"5791-5800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience"],"prefix":"10.1245","volume":"33","author":[{"given":"Lisa M.","family":"Kenney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Dinerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham A.","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Li M.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udai S.","family":"Kammula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1353-539X","authenticated-orcid":false,"given":"Nicholas D.","family":"Klemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"19","key":"19242_CR1","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","volume":"27","author":"SJ Seitter","year":"2021","unstructured":"Seitter SJ, Sherry RM, Yang JC, et al. Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res. 2021;27(19):5289\u201398. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1171.","journal-title":"Clin Cancer Res."},{"issue":"24","key":"19242_CR2","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656\u201366. https:\/\/doi.org\/10.1200\/JCO.21.00612.","journal-title":"J Clin Oncol."},{"issue":"12","key":"19242_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12):e005755. https:\/\/doi.org\/10.1136\/jitc-2022-005755.","journal-title":"J Immunother Cancer."},{"issue":"23","key":"19242_CR4","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2210233.","journal-title":"N Engl J Med."},{"key":"19242_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03627-5","author":"FJ Lowery","year":"2025","unstructured":"Lowery FJ, Goff SL, Gasmi B, et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03627-5.","journal-title":"Nat Med."},{"issue":"16","key":"19242_CR6","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.21.02170","volume":"40","author":"N Zacharakis","year":"2022","unstructured":"Zacharakis N, Huq LM, Seitter SJ, et al. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol. 2022;40(16):1741\u201354. https:\/\/doi.org\/10.1200\/JCO.21.02170.","journal-title":"J Clin Oncol."},{"issue":"5","key":"19242_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","volume":"26","author":"E Lou","year":"2025","unstructured":"Lou E, Choudhry MS, Starr TK, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025;26(5):559\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(25)00083-X.","journal-title":"Lancet Oncol."},{"issue":"8","key":"19242_CR8","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410\u20138. https:\/\/doi.org\/10.1038\/s41591-021-01462-y.","journal-title":"Nat Med."},{"issue":"2","key":"19242_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1245\/s10434-017-6266-8","volume":"25","author":"JG Crompton","year":"2018","unstructured":"Crompton JG, Klemen N, Kammula US. Metastasectomy for tumor-infiltrating lymphocytes: an emerging operative indication in surgical oncology. Ann Surg Oncol. 2018;25(2):565\u201372. https:\/\/doi.org\/10.1245\/s10434-017-6266-8.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"19242_CR10","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.21873\/anticanres.13689","volume":"39","author":"D Zippel","year":"2019","unstructured":"Zippel D, Friedman-Eldar O, Rayman S, et al. Tissue harvesting for adoptive tumor-infiltrating lymphocyte therapy in metastatic melanoma. Anticancer Res. 2019;39(9):4995\u20135001. https:\/\/doi.org\/10.21873\/anticanres.13689.","journal-title":"Anticancer Res."},{"issue":"4","key":"19242_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/PPO.0000000000000608","volume":"28","author":"JE Mullinax","year":"2022","unstructured":"Mullinax JE, Egger ME, McCarter M, et al. Surgical considerations for tumor tissue procurement to obtain tumor-infiltrating lymphocytes for adoptive cell therapy. Cancer J. 2022;28(4):285\u201393. https:\/\/doi.org\/10.1097\/PPO.0000000000000608.","journal-title":"Cancer J."},{"key":"19242_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1477-7819-10-113","volume":"10","author":"MM Alvarez-Downing","year":"2012","unstructured":"Alvarez-Downing MM, Inchauste SM, Dudley ME, et al. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World J Surg Oncol. 2012;10:113. https:\/\/doi.org\/10.1186\/1477-7819-10-113.","journal-title":"World J Surg Oncol."},{"issue":"6","key":"19242_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran SS, Somerville RPT, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18(6):792\u2013802. https:\/\/doi.org\/10.1016\/S1470-2045(17)30251-6.","journal-title":"Lancet Oncol."},{"issue":"8","key":"19242_CR14","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","volume":"9","author":"MR Parkhurst","year":"2019","unstructured":"Parkhurst MR, Robbins PF, Tran E, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 2019;9(8):1022\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1494.","journal-title":"Cancer Discov."},{"issue":"8","key":"19242_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s00262-025-04091-3","volume":"74","author":"AM Gustafson","year":"2025","unstructured":"Gustafson AM, Dinerman AJ, Hitscherich KJ, et al. Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers. Cancer Immunol Immunother. 2025;74(8):244. https:\/\/doi.org\/10.1007\/s00262-025-04091-3.","journal-title":"Cancer Immunol Immunother."},{"issue":"8","key":"19242_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CJI.0b013e3181f05b91","volume":"33","author":"SL Goff","year":"2010","unstructured":"Goff SL, Smith FO, Klapper JA, et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010;33(8):840\u20137. https:\/\/doi.org\/10.1097\/CJI.0b013e3181f05b91.","journal-title":"J Immunother."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19242-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:28:28Z","timestamp":1778869708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19242"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19242-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephanie Goff\u2009-\u2009Research support, Iovance\u2014James Yang - institution receives research support under CRADAs with Iovance Biotech and Neogene Therapeutics; patent interests related to T-cell therapies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}